Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 30, 2026
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
View original at finance.yahoo.comRegeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Regeneron Pharmaceuticals, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Regeneron has announced $7B+ in ongoing and planned domestic investments
80% confidenceDupixent is the most widely used innovative branded antibody medicine worldwide
80% confidenceLibtayo is first and only immunotherapy approved for high-risk adjuvant cutaneous squamous cell carcinoma
80% confidenceDupixent has 1.4M+ active patients worldwide
80% confidenceRegeneron has approximately 45 product candidates in clinical development
80% confidenceLibtayo is the leading immunotherapy for non-melanoma skin cancers
80% confidenceEYLEA sales decline driven by competitive pressures, compounded bevacizumab market share loss due to patient affordability constraints, patient transition to EYLEA HD, and lower net selling price
80% confidence
Data points we hold from this source
| Sanofi · collaboration revenue | 5.9 billion_USD |